SUFENTANIL CITRATE INJECTION DIN 02483181
Status: Approved
Holder: HIKMA CANADA LIMITED
Health Canada record
| Active ingredient(s) | SUFENTANIL (SUFENTANIL CITRATE) 50 MCG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravenous; Epidural |
|---|
| Schedule | NARCOTICS (CDSA I) |
|---|
| Class | Human |
|---|
| ATC | N01AH03 SUFENTANIL |
|---|
| Original market date | |
|---|
| Current status date | 07-Jun-2022 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Hikma Canada Limited — licence 3-002579, currently licensed, last inspection rating C (2022-04-26).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SUFENTANIL (SUFENTANIL CITRATE)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02244147 | SUFENTANIL CITRATE INJECTION USP | SANDOZ CANADA INCORPORATED | Solution | SUFENTANIL (SUFENTANIL CITRATE) 50 MCG | Marketed |
| 02442213 | SUFENTANIL CITRATE INJECTION USP | STERIMAX INC | Solution | SUFENTANIL (SUFENTANIL CITRATE) 50 MCG | Marketed |
| 00619744 | SUFENTA INJ 50MCG/ML | JANSSEN PHARMACEUTICA, DIVISION OF JANSSEN-ORTHO INC. | Liquid | SUFENTANIL (SUFENTANIL CITRATE) 50 MCG | Cancelled Post Market |
| 01951319 | SUFENTA INJ 50MCG/ML | JANSSEN INC | Liquid | SUFENTANIL (SUFENTANIL CITRATE) 50 MCG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 28340 | 2022-06-07 | Abbreviated New Drug Submission (ANDS) | Administrative: Merger/Buy-out |
| 25855 | 2021-05-03 | Abbreviated New Drug Submission (ANDS) | CHANGE IN PRODUCT OWNERSHIP |
| 21549 | 2018-11-26 | Abbreviated New Drug Submission (ANDS) | |
Request a quote for SUFENTANIL CITRATE INJECTION
How to read a Canadian DIN record